EI
XGN icon

EAM Investors’s Exagen XGN Stock Holding History

EAM Investors’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-117,558
Closed -$1.29M – 363
2025
Q3 		$1.29M Buy
117,558
+19,785
+20% +$175K 0.15% 176
2025
Q2 		$682K Buy
+97,773
New +$594K 0.1% 190
2020
Q1 		– Sell
-31,807
Closed -$808K – 293
2019
Q4 		$808K Buy
+31,807
New +$566K 0.18% 220

Other funds holding XGN

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

EAM Investors's XGN Position: Q4 2025 in Review

EAM Investors sold out of Exagen (XGN) in Q4 2025, closing a stake of 117,558 shares — an estimated $1.29M sold.

EAM Investors first reported a position in XGN in Q4 2019 and held it in 3 quarters. The position peaked at $1.29M in Q3 2025. 80 funds tracked by Wall St. Rank hold XGN as of Q4 2025.

  • EAM Investors reported no remaining Exagen position as of Q4 2025 after selling out during the quarter.
  • EAM Investors sold 117,558 Exagen shares in Q4 2025, an estimated $1.29M.
  • EAM Investors first reported a position in Exagen in Q4 2019 and held it in 3 quarters.
  • EAM Investors's Exagen position peaked at $1.29M in Q3 2025.
  • 80 funds tracked by Wall St. Rank held Exagen as of Q4 2025.

Based on EAM Investors's 13F filing for Q4 2025, filed 12 Feb 2026.